Literature DB >> 12627362

Safety of probiotics that contain lactobacilli or bifidobacteria.

S P Borriello1, W P Hammes, W Holzapfel, P Marteau, J Schrezenmeir, M Vaara, V Valtonen.   

Abstract

Lactobacilli and bifidobacteria are extremely rare causes of infection in humans, as are probiotics based on these organisms. This lack of pathogenicity extends across all age groups and to immunocompromised individuals. Strains used for new probiotics should be chosen from the commensal flora of humans and should not carry intrinsic resistance to antibiotics that would prevent treatment of a rare probiotic infection. Vigilance regarding the detection of possible rare cases of infection due to probiotics should be maintained, and isolates should be sent to reference centers for molecular characterization and confirmation.

Entities:  

Mesh:

Year:  2003        PMID: 12627362     DOI: 10.1086/368080

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  82 in total

1.  Feasibility of Genome-Wide Screening for Biosafety Assessment of Probiotics: A Case Study of Lactobacillus helveticus MTCC 5463.

Authors:  S Senan; J B Prajapati; C G Joshi
Journal:  Probiotics Antimicrob Proteins       Date:  2015-12       Impact factor: 4.609

2.  Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Authors:  Elaine O Petrof
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

Review 3.  Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Gregoria I Betsi; Theodoros Tokas; Stavros Athanasiou
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Safety of probiotics: comparison of two popular strains.

Authors:  Cathy Hammerman; Alona Bin-Nun; Michael Kaplan
Journal:  BMJ       Date:  2006-11-11

5.  Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.

Authors:  P Marteau; M Lémann; P Seksik; D Laharie; J F Colombel; Y Bouhnik; G Cadiot; J C Soulé; A Bourreille; E Metman; E Lerebours; F Carbonnel; J L Dupas; M Veyrac; B Coffin; J Moreau; V Abitbol; S Blum-Sperisen; J Y Mary
Journal:  Gut       Date:  2005-12-23       Impact factor: 23.059

6.  Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial.

Authors:  M Beausoleil; N Fortier; S Guénette; A L'ecuyer; M Savoie; M Franco; J Lachaine; K Weiss
Journal:  Can J Gastroenterol       Date:  2007-11       Impact factor: 3.522

7.  Exploring the Probiotic and Compound Feed Fermentative Applications of Lactobacillus plantarum SK1305 Isolated from Korean Green Chili Pickled Pepper.

Authors:  Kai-Min Niu; Damini Kothari; Sang-Buem Cho; Sung-Gu Han; In-Geun Song; Sam-Churl Kim; Soo-Ki Kim
Journal:  Probiotics Antimicrob Proteins       Date:  2019-09       Impact factor: 4.609

8.  Bile-mediated aminoglycoside sensitivity in Lactobacillus species likely results from increased membrane permeability attributable to cholic acid.

Authors:  Christopher A Elkins; Lisa B Mullis
Journal:  Appl Environ Microbiol       Date:  2004-12       Impact factor: 4.792

9.  Bifidobacterium animalis causes extensive duodenitis and mild colonic inflammation in monoassociated interleukin-10-deficient mice.

Authors:  James P Moran; Jens Walter; Gerald W Tannock; Susan L Tonkonogy; R Balfour Sartor
Journal:  Inflamm Bowel Dis       Date:  2009-07       Impact factor: 5.325

10.  Evaluation of Probiotic Potential of Bacteriocinogenic Lactic Acid Bacteria Strains Isolated from Meat Products.

Authors:  Izildinha Moreno; Elza Teresinha Grael Marasca; Patrícia Blumer Zacarchenco Rodrigues de Sá; Josiane de Souza Moitinho; Miriam Gonçalves Marquezini; Márcia Regina Cucatti Alves; Renata Bromberg
Journal:  Probiotics Antimicrob Proteins       Date:  2018-12       Impact factor: 4.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.